Replies to post #518858 on Anavex Life Sciences Corp (AVXL)

[BIOChecker4]

Fragile X, Rett, PD, PDD, and schizophrenia are early stage programs that are going nowhere fast. It’ll take many years, many tens of millions of dollars, and a rebuilding of diverse in-house expertise to advance those programs toward regulatory review. Where is the money going to come from? Just as importantly, how much dilution will that represent?

I hate being a Negative Nelly but I just don’t see a realistic way forward except an all-stock merger with a stronger company.

If it were me, I’d be quietly speaking with biotech investment bankers to find the best deal I could get.

[frrol]

Tough to see through sand. Stand up.

[Bourbon_on_my_cornflakes]

Fragile X not an option. the only real possibilities are those where there are some trial data already so a proper P3 can be done. that would be PD, PDD, Rett or Schizo. I would prefer PD as the symptoms are obvious so the trial could be short but determinative.